Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Claudio G. Clemente,F.A.C.P. Martin C. Mihm Jr. M.D.,Rosaria Bufalino,Stefano Zurrida,Paola Collini,Natale Cascinelli +5 more
Reads0
Chats0
TLDR
In an attempt to delineate the histologic diagnostic criteria, to classify different categories of lymphocytic infiltrates, previously described by Elder et al. as brisk, nonbrisk, and absent, and to verify their prognostic significance, 285 consecutive cases of primary cutaneous melanomas are reviewed.Abstract:
BACKGROUND
Primary cutaneous melanoma is often infiltrated by lymphocytes that provide the opportunity to study what may be the local immunologic reaction to the tumor and to correlate the presence of these lymphocytes with overall survival. In an attempt to delineate the histologic diagnostic criteria, to classify different categories of lymphocytic infiltrates, previously described by Elder et al. as brisk, nonbrisk, and absent, and to verify their prognostic significance, we reviewed 285 consecutive cases of primary cutaneous melanomas (American Joint Committee on Cancer Stage I and II).
METHODS
In addition to clinical variables (age, sex, and location of tumor) and the presence of tumor infiltrating lymphocytes in the vertical growth phase, the histopathologic attributes reviewed included mitotic rate, thickness, and regression. The results were derived from independent histopathologic review by two pathologists (C.G.C., M.C.M., Jr.) on separate occasions. A multivariate analysis of survival was performed with the Cox's regression model.
RESULTS
The 5- and 10-year survival rates for melanoma with a vertical growth phase and a brisk infiltrate were 77% and 55%, respectively. For tumors with a nonbrisk infiltrate, the 5- and 10-year survival rates were 53% and 45%, respectively, and for tumors with absent tumor infiltrating lymphocytes, the 5- and 10-year survival rates were 37% and 27%, respectively. Mitotic index, thickness, and tumor infiltrating lymphocytes were statistically (univariate analysis) significant prognostic factors (P = 0.003, 0.000001, 0.0003, respectively), whereas the presence or absence of regression is not. In the univariate statistical analysis, the sex of patients and site of melanoma also were statistically significant (P = 0.00001 and 0.002 respectively), whereas age (P = 0.98) was not statistically significant. The multivariate analysis of thickness, mitotic rate, and tumor infiltrating lymphocytes showed that thickness and presence of tumor infiltrating lymphocytes were significant and independent histologic prognostic factors. With regard to the clinical factors, sex retained its independent prognostic significance. The histologic characteristics of melanoma with vertical growth phase (brisk, nonbrisk, and absent) are exemplified.
CONCLUSIONS
We demonstrated that when categories of tumor infiltrating lymphocytes are strictly defined, they indeed have very strong predictive value for primary cutaneous melanomas with a vertical growth phase. This work confirms the work of Clark et al. and fully illustrates the brisk, nonbrisk, and absent categories of infiltration. Finally, a multivariate analysis comparing thickness, mitotic rate and presence of tumor infiltrating lymphocytes showed that only thickness and presence of tumor infiltrating lymphocytes are significant and independent positive histologic prognostic factors. Cancer 1996;77:1303-10.read more
Citations
More filters
Journal ArticleDOI
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Luigi Formisano,Valentina D’Amato,Alberto Servetto,Simona Brillante,Lucia Raimondo,Concetta Di Mauro,Roberta Marciano,Roberta Clara Orsini,Sandro Cosconati,Antonio Randazzo,Sarah J. Parsons,Nunzia Montuori,Bianca Maria Veneziani,Sabino De Placido,Roberta De Rosa,Roberto Bianco +15 more
TL;DR: The most effective drug combinations to overcome resistance to EGFR inhibitors are identified, both in vitro and in nude mice: in T790M EGFR erlotinib-resistant cells, saracatinib with the anti-EGFR mAb cetuximab; in Ras mutant erlot inib- resistant models, dasatinIB with the MEK inhibitor selumetinib.
Journal ArticleDOI
Regresión en el melanoma: problemas en su definición e implicación pronóstica
TL;DR: In this article, a revision resumimos los principales articulos publicados sobre la influencia de the regresion in el pronostico del melanoma and encontramos resultados muy dispares.
Journal ArticleDOI
Immune Signatures Predict Prognosis in Localized Cancer
David S. Hsu,Mickey K. Kim,Bala S. Balakumaran,Chaitanya R. Acharya,Carey K. Anders,Timothy M. Clay,H. Kim Lyerly,Charles G. Drake,Michael A. Morse,Phillip G. Febbo +9 more
TL;DR: The expression of genes recently associated with host immune responses (TH1-mediated adaptive immunity, inflammation, and immune suppression) was used to perform hierarchical clustering of multiple large cohorts of cancer specimens to determine if immune-related gene expression resulted in clinical significant groupings of tumors.
Journal ArticleDOI
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
James L. Gulley,Christopher R. Heery,Ravi A. Madan,Beatriz A. Walter,Maria J. Merino,William L. Dahut,Kwong-Yok Tsang,Jeffrey Schlom,Peter A. Pinto +8 more
TL;DR: Improved serum PSA kinetics and intense post-vaccination inflammatory infiltrates were seen in the majority of patients, and intraprostatic administration of PSA-TRICOM is safe and feasible and can generate a significant immunologic response.
Journal ArticleDOI
CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis.
TL;DR: Rheumatoid arthritis pathogenesis and the potential application of new developments in CRISPR-mediated Treg genome editing in personalized therapy of RA are discussed.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
Nathan Mantel,William Haenszel +1 more
TL;DR: In this paper, the role and limitations of retrospective investigations of factors possibly associated with the occurrence of a disease are discussed and their relationship to forward-type studies emphasized, and examples of situations in which misleading associations could arise through the use of inappropriate control groups are presented.
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Journal ArticleDOI
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
TL;DR: The depth of invasion was studied using the criteria for staging of Clark et al.2 to see if maximal cross-sectional area, thickness, stage of invasion, or a combination of these can be of value in assessing the prognosis of cutaneous melanoma.
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: This report is the first simple account yet published for non-statistical physicians of how to analyse efficiently data from clinical trials of survival duration, and it may be preferable to use these statistical methods to study time to local recurrence of tumour, or toStudy time to detectable metastatic spread, in addition to studying total survival.
Related Papers (5)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J. Curiel,George Coukos,Linhua Zou,Xavier Alvarez,Pui Cheng,Peter Mottram,Melina Evdemon-Hogan,Jose R. Conejo-Garcia,Lin Zhang,Matthew E. Burow,Yun Zhu,Shuang Wei,Ilona Kryczek,Ben Daniel,Alan N. Gordon,Leann Myers,Andrew A. Lackner,Mary L. Disis,Keith L. Knutson,Lieping Chen,Weiping Zou +20 more